Sponsor Title Phase Sample Size Name of Investigator And
Sr. Applicant/ CT approval File No Drug Name Protocol Title Phase Sample size Name of investigator and address no. Sponsor date 1. Dr. Parmesh Shamanna, Bangalore Cliniserach, A multinational, open 560043 label, randomized, 2.Dr. Prasanna Kumar, bangalore Diabetes Hospital, active-controlled, Bangalore 3arm parallel group, 3. Dr. sunil jain Totall Diabetes Hormone Institute, 24 week study Indore comparing the 4. Dr. sanjay Chatterjee, Apollo Gleneagles Glimepride/M GLIME_R_05 Globally 400, 1 CT/196/11 Sanofi Aventis combination of III Hospitals, Kolkata 19-06-12 etformin 809 India 200 glimepiride and 5. Dr. Monica Gupta, samvedna Hospital, varanasi metformin versus 6. Dr. rajesh nair, Mar Augustine Golden Jubilee glimepiride and Hospital, Ernakulam, Kerala metformin alone in 7. Dr. Pravin Supe, Super Hospital Institute of patients with Type 2 Excellance in Diabetes and Obesity, Nashik diabetes 8. Dr. Mohan Magdum, Medipoint Hospitals Pvt. Ltd.,Pune A 5 year study to compare the durability of glycemic control of a 1. Dr. Parmesh Shamanna, Bangalore Cliniserach, combination regimen 560043 with vildagliptin and Globally CLAF2378231 2. Dr. Satish Kumar, Indraprastha apollo Hospitals, 2 CT/205/11 Vildagliptin Novartis metformin versus IV 4000, India 14-06-12 56 New Delhi standard of care 180 3. Dr. Sunil Jain, Totall Diabetes Hormone Institute, monotherapy with Indore. metformin , initiated in treatment naïve patients with type 2 diabetes mellitus 1. Dr. B.H.K. Rao, Wenlock District Hospital, A multuicenter, Mangalore double blind, 2. Dr. D. K. Kochar, Kothari Medical and resaerch randomised, parallel Institute, Bikaner group, active 3. Dr. Nithya Gogtay, Seth G. S. Medical college and controlled study to Globally B.Y.L.
[Show full text]